Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday?

We recently published a list of Traders Heavily Sold Down These 10 Stocks on Thursday. In this article, we are going to take a look at where Charles River Laboratories International, Inc. (NYSE:CRL) stands against other stocks that traders heavily sold down on Thursday.

The stock market wiped away earlier gains, ending Thursday’s trading in another bloodbath session, as investors sold off positions amid President Donald Trump’s announcement that he had actually raised tariffs on Chinese goods to 145 percent.

The Nasdaq was battered the most among all major indices, losing 4.31 percent. The S&P 500 followed with a 3.46-percent drop while the Dow Jones came in last, down 2.50 percent.

Meanwhile, 10 companies were heavily sold down on Thursday, recording double-digit losses as investors parked funds to minimize risks from the ongoing uncertainties. In this article, we have listed Thursday’s 10 worst performers and detailed the reasons behind their drop.

To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million trading volume.

A laboratory scientist surrounded by drug-discovery equipment and resources.

Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River’s share prices fell by 28.13 percent on Thursday to end at $99.95 apiece as investors sold off on news that the Food and Drug Administration (FDA) officially phased out animal testing requirements to switch to Artificial Intelligence methods.

The move was a low blow to the company, having specialized in traditional animal trials.

According to the FDA, the initiative was designed to replace animal testing with more effective human-relevant methods in the development of monoclonal antibody therapies and other drugs.

The move was not only expected to improve drug safety and expedite the evaluation process, but it could also result in lower research and development costs, thereby reducing drug prices for the end consumers.

According to the FDA, it will begin to encourage the inclusion of New Approach Methodologies (NAMs) data in investigational new drug applications.

Overall, CRL ranks 1st on our list of stocks that traders heavily sold down on Thursday. While we acknowledge the potential of CRL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CRL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.